Insolvency Opportunity Destiny Pharma is in liquidation with joint administrators appointed, signaling a potential need for license transfer discussions, asset monetization options, or collaboration deals with remaining product candidates (NTCD-M3 and XF-73) or regional rights.

Lead Candidate Value NTCD-M3 is a Phase 3 ready asset for CDI recurrence prevention, presenting a clear licensing or partnering opportunity for large biopharma or specialty pharma aiming to expand hospital infection prevention portfolios.

MRSA and CDI Angles XF-73 nasal gel targets post-surgical MRSA infections and nasal colonization, offering a potential mid-market or regional partner for wound care, infection control, or dermatology-focused distributors looking to broaden antimicrobial/productivity lines.

Strategic Partnerships Past collaborations (Sebela for NTCD-M3 and CMS China for XR-73 dermal) indicate investor and partner appetite; potential buyers or licensees may value a structured deal to continue development, manufacturing rights, or co-development once in liquidation.

Financial Levers With revenue under $1M but significant funding (~$55M) and ongoing insolvency proceedings, buyers could pursue portfolio acquisition, contingent milestones, and royalty structures to maximize value from remaining assets and research programs.